The Japan Diabetes Devices Market is expected to witness growth from $1.41 Bn in 2022 to $2.55 Bn in 2030 with a CAGR of 7.70% for the forecasted year 2022-2030. Japan has one of the world's oldest populations, with a sizable percentage of the population being over 65. Because older adults have a higher chance of getting diabetes, there is a sizable market for diabetes devices. The market is segmented by type and by the end user. Some key players in this market include Koike Medical, Terumo Corporation, Johnson & Johnson, Medtronic, Roche, Ascensia Diabetes Care and Dexcom.
The Japan Cardiac Surgery Instruments Market is expected to witness growth from $129 Mn in 2022 to $223 Mn in 2030 with a CAGR of 7.10% for the forecasted year 2022-2030. Japan's population is ageing at one of the fastest rates in the world, which is anticipated to increase demand for instruments used in cardiac surgery since older people are more likely to develop cardiac diseases. The market is segmented by type, application and by end user. Some key players in this market include Terumo Corporation, Fukuda, LivaNova, B. Braun, Medline Industries, KLS Martin, and STILLE.
Japan's Artificial Intelligence (AI) in the healthcare market is projected to grow from $0.43 Bn in 2022 to $8.72 Bn by 2030, registering a CAGR of 45.72% during the forecast period of 2022-30. The market will be driven by the country's aging population and it's technologically advanced infrastructure. The market is segmented by healthcare components & by healthcare applications. Some of the major players include GE Healthcare, Hitachi, Ltd & A-Traction.
The Japan Biomaterials Healthcare Market is expected to witness growth from $9.71 Bn in 2022 to $27.12 Bn in 2030 with a CAGR of 13.70% for the forecasted year 2022-2030. In Japan, the prevalence of illnesses like gingivitis, tooth decay, oral cancer, halitosis, and dental caries is increasing, which is fueling demand for biomaterials and boosting the country's biomaterial healthcare market. The market is segmented by type and by application. Some key players in this market include: Terumo, Asahi Kasei Corporation, Menicon, BASF SE, Johnson and Johnson, Medtronic and Evonik Industries.
Japan anti-aging therapeutics market is projected to grow from $38 Mn in 2022 to $132 Mn in 2030 with a CAGR of 17.03% for the year 2022-2030. Japan has the fastest-growing geriatric population which results in increased demand for anti-aging treatments. Further, in Japan, there is the presence of highly advanced technology which results in the expansion of the market. The Japan anti-aging therapeutics market is segmented by product, treatment, target group, type of aging, type of molecules, mechanism of action, ingredient, and by distribution channel. Modulus Discovery, Noile-Immune Biotech, and NeuroTrack are some of the top players in the market.
Japan 3D Printing Medical Device Market is expected to witness growth from $185 Mn in 2022 to $639 Mn in 2030 with a CAGR of 16.80% for the forecasted year 2022-2030. The Japan market for 3D-printed medical devices is expanding as a result of the ongoing creation of new 3D printing technologies and materials. Production of intricate medical devices is becoming simpler and more affordable thanks to advancements in 3D printing technology. The market is segmented by application, by technology and by end user. Some key players in this market include: Materialise Japan, Roland dg, Siemens Healthineers, GE Healthcare, Stryker and Renishaw.
The Japan healthcare insurance market is projected to grow from $125.95 Bn in 2022 to $234.85 Bn by 2030, registering a CAGR of 8.1% during the forecast period of 2022 - 2030. The main factors driving the growth would be the ageing population, technological advancements, rising healthcare costs and government initiatives. The market is segmented by component, provider, coverage, by health insurance plans and end-user. Some of the major players include Nippon Life Insurance, Daiichi Life Insurance, Tokio Marine Insurance and Sompo Japan Insurance.
Japan's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $1.8 Bn in 2022 to $3.4 Bn in 2030 with a CAGR of 8% for the year 2022-30. This market growth is attributed to the rise in ADHD prevalence in Japan and consequently the demand for new drugs and their approvals. The Japan ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Some of the leading players in the market include Kouken, Lupin, and Takeda Pharmaceuticals.
The Japan healthcare claims management market is projected to grow from $1.66 Bn in 2022 to $9.22 Bn by 2030, registering a CAGR of 12.2% during the forecast period of 2022 - 2030. The main factors driving the growth would be the ageing population, government initiatives, technological advancements and increasing healthcare expenditure. The market is segmented by component, by type, delivery mode and end-user. Some of the major players include NTT Data, iChain, Cognizant, Accenture and Genpact.
By 2030, it is anticipated that the Japan Liver Disease Therapeutics market will reach a value of $2.3 Bn from $1.4 Bn in 2022, growing at a CAGR of 6.2% during 2022-2030. Liver Disease Therapeutics in Japan is dominated by domestic pharmaceutical companies such as Aspen Pharmacare Japan, Mayne Pharma, and Phebra. The Liver Disease Therapeutics market in Japan is segmented into different types of disease and different therapy types. Some of the significant factors affecting the Japan Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.
Japan's oncology clinical trials market is projected to grow from $0.79 Bn in 2022 to $1.25 Bn by 2030, registering a CAGR of 6% during the forecast period of 2022-30. The market will be driven by a well-established healthcare system, advanced infrastructure, and a high prevalence of cancer. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis International AG, Chugai Pharmaceutical Co., Ltd. & Ono Pharmaceutical Co., Ltd.
The Japan diabetes drugs market size was valued at $3.84 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.6% from 2022 to 2030 and will reach $6.4 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The Japan diabetes drug market will grow because of the Japanese government's initiatives to improve healthcare infrastructure and increase awareness about diabetes management. The key market players are Takeda Pharmaceutical (JPN), Astellas Pharma (JPN), Daiichi Sankyo (JPN), Sumitomo Dainippon (JPN) others.
The Japan-connected healthcare market is projected to grow from $4.13 Bn in 2022 to $31.44 Bn by 2030, registering a CAGR of 28.9% during the forecast period of 2022 - 2030. The main factors driving the growth would be the ageing population, shortage of healthcare workers, technological innovation and government support. The market is segmented by type, function and by application. Some of the major players include Sony, Hitachi, Fujitsu Limited, Apple, Cisco Systems, IBM and GE Healthcare.
Japan's Anemia drugs market was valued at $993 Mn in 2022 and is estimated to expand at a CAGR of 9.40% from 2022-30 and will reach $2038 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Pfizer, Astellas Pharma, Takeda Pharmaceutical, Daiichi Sankyo Company, Chugai Pharmaceutical, Otsuka Holdings, Roche, and GSK among others.
The Japan Neurology Clinical Trials market is projected to grow from $325.1 Mn in 2022 to $518.1 Mn by 2030, registering a CAGR of 6% during the forecast period of 2022 - 2030. The market will be driven by the high prevalence of neurological diseases and a robust healthcare system. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Pfizer, Eisai Co., Ltd & Daiichi Sankyo.
By 2030, it is anticipated that the Japan infectious disease therapeutics market will reach a value of $10.88 Bn from $7.45 Bn in 2022, growing at a CAGR of 4.9% during 2022-2030. Infectious Disease Therapeutics in Japan is dominated by a few domestic pharmaceutical companies such as Astellas Pharma, Daiichi Sankyo and Takeda Pharmaceutical. The Infectious Disease Therapeutics market in Japan is segmented into different therapeutic areas and different diseases type. The major factors affecting the Japanese infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of Japan.
The Japan patient engagement solutions market is projected to grow from $1.06 Bn in 2022 to $2.75 Bn by 2030, registering a CAGR of 12.7% during the forecast period of 2022 - 2030. The main factors driving the growth would be technological advancements, increasing healthcare spending, the ageing population, government support and changing patient preferences. The market is segmented by component, delivery mode, application, therapeutic area, functionality and by end-user. Some of the major players include CureApp, Takeda Pharmaceutical, NTT Data, M3 and Oracle.
Japan's Artificial Intelligence (AI) in the diagnostics market is projected to grow from $0.06 Bn in 2022 to $0.71 Bn by 2030, registering a CAGR of 35.5% during the forecast period of 2022 - 2030. The market will be driven by supportive government initiatives and a heavy emphasis on technological innovations. The market is segmented by component & by diagnosis. Some of the major players include Fujifilm, Toshiba & NEC Corporation.
The Japan 3D Imaging market is projected to grow from $ 1.89 Bn in 2022 to $ 6.63 Bn by 2030, registering a CAGR of 17% during the forecast period of 2022 - 2030. The market will be driven by rising demand for precise medical imaging technologies & an increase in chronic illnesses in the growing population. The market is segmented by product, application, end-user & by portability. Some major players include Toshiba Medical Systems Corporation, Hitachi Medical Corporation & Shimadzu Corporation.
The Japan Robotic Surgery Service market size was valued at $267 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 19.8% % from 2022 to 2030 and will reach $1131 Mn in 2030. The robotic surgery service market will grow due to the development of new and improved robotic surgical systems is making these procedures more accessible and affordable, and helping to increase awareness about their benefits among healthcare providers and patients. The market is segmented by product and service type, application type, and end user. Some of the major players are Stryker Corporation, Smith & Nephew, TransEnterix Surgical, Inc., and others
The Japan acne therapeutics market size was valued at $623 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.2% from 2022 to 2030 and will reach $1,087 Mn in 2030. The main factors contributing to this market growth are the rising prevalence of acne and the demand for innovative treatment options in Japan. The market is segmented by treatment, route of administration, age group, and by distribution channel. Otsuka Pharmaceuticals, Torii Pharmaceuticals, and Teva Pharmaceuticals are key competitors in Japan acne therapeutics market.
The Japan home healthcare market was valued at $22.4 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 8.43% from 2022 to 2030 and will reach $43.07 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, The increased prevalence of chronic ailments. The market is segmented by equipment and by services. Some key players in this market are Doctor mate, Medtronic Japan, A&D Company, and Toto.
The Japan Palliative care market is projected to grow from $813.03 Mn in 2022 to $1561.52 Mn by 2030, registering a CAGR of 8.5% during the forecast period of 2022 - 2030. The main factors driving the growth would be the growing homecare industry, technological advancements, the aging population, and government support. The market is segmented by service type and by the end user. Some of the major players include Aichi International Hospital, Anjo Koesei Hospital, Nikko Memorial Hospital, Fukuyama City Hospital, and Home Instead.
The Japan Rheumatology Drugs Market is projected to grow from $3.795 Bn in 2022 to $4.920 Bn by 2030, registering a CAGR of 3.30% during the forecast period of 2022-2030. Leading companies working on new treatments for rheumatoid arthritis include Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol-Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceutical
Japan's Cancer Pain Management market is projected to grow from $405.27 Mn in 2022 to $636.26 Mn by 2030, registering a CAGR of 5.8% during the forecast period of 2022 - 2030. The main factors driving the growth would be high healthcare expenditure, advanced healthcare infrastructure, an aging population, and government support. The market is segmented by drug type and by disease. Some of the major players include Daiichi Sankyo (JPN), Hisamitsu Pharmaceutical Co (JPN), Mundipharma, Pfizer, and Teva Pharmaceuticals.